Goldberg Gives Moertel Lecture At Alliance Meeting

July 05, 2012
Goldberg Gives Moertel Lecture At Alliance Meeting richard goldberg

COLUMBUS, Ohio – Dr. Richard Goldberg, (43235) an internationally renowned gastrointestinal oncologist at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James), presented the first Charles G. Moertel Lecture of the Alliance for Clinical Trials in Oncology during the plenary session of the group's meeting in Chicago on June 30.

This is the first annual Moertel lecture being given through the newly merged cooperative group known as the Alliance for Clinical Trials in Cancer, which is a nationwide clinical research community sponsored by the National Cancer Institute.

The Moertel Lecture was initiated in 1995 by the cooperative group Cancer and Leukemia Group B (CALGB) to honor the legacy of Moertel, one of the founding fathers of the North Central Cancer Treatment Group, which is a national clinical research group sponsored by the NCI. Moertel, a renowned cancer researcher and former director of the Mayo Comprehensive Cancer Center, died in 1994.

"We believe that Rich Goldberg – like no one else – embodies the spirit of Dr. Moertel as an integrative force in oncology research, in particular, GI medical oncology," said Dr. Monica M. Bertagnolli, chief of surgical oncology at Dana-Farber/Brigham and Women's Cancer Center and group chair of the Alliance for Clinical Trials in Oncology. "We are pleased that he has accepted the invitation to serve as the first Charles G. Moertel Lecturer of the Alliance."

During his presentation titled, "Meaningful Outcomes: Lives Saved Due To Clinical Trials in Early Stage Colon Cancer," Goldberg discussed his personal relationship with Moertel, whose footsteps he followed in at the Mayo Clinic.

Goldberg, who is the physician-in-chief at OSUCCC – James, also explained Moertel's work in making the first major discovery on how to increase the surgical cure rate of stage III colon cancer by adding postoperative chemotherapy, and how that initial discovery has led to further improved outcomes over 35 years of additional research.

A member and former chair of the NCI's Colorectal Task Force, Goldberg is an international leader in evaluating new agents for the treatment of colorectal cancer and researching inherited colorectal cancer syndromes.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 210-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S. News & World Report.

# # #

Contact: Eileen Scahill, Wexner Medical Center Public Affairs and Media Relations, 614-293-3737, or

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)

Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.


If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Support Those Who Support Us – October 2015

The OSUCCC – James is so grateful to the more than 400 partners who raise dollars to support care for our patients & the research that is bringing us closer to our shared vision of a cancer-free world.

The Spielman Fund: Allocating Dollars Where They Are Needed Most

When donors contribute to the Spielman Fund, they can trust that their gift will make an important and strategic impact.

Studies Suggest New Ways to Inhibit Oncogenes, Enhance Tumor-Suppressor Activity

Two new studies by OSUCCC - James cancer scientists suggest new approaches for treating cancer by inhibiting overactive cancer-promoting genes and by enhancing the activity of sluggish tumor-suppressor...